Association Between Mortality and Antidepressant Use After HCC Diagnosis With Chemotherapy or Sorafenib
HCC
To investigate the potential effect of combination therapies, we examined the interaction between postdiagnosis antidepressant use and HCC treatments such as chemotherapy and sorafenib. None of the interaction tests between antidepressant and chemotherapy or antidepressant and sorafenib revealed additional beneficial associations with overall mortality or cancer-specific mortality. This finding was consistent across different antidepressant subgroups (eTable 2 in 